Table 2 Associations between MetS and urologic, kidney, prostate, and bladder cancer risk

Urologic cancer

 MetS status

Non-MetS

66,616

828,271.46

287

Ref

Ref

MetS

31,359

380,907.19

198

1.28(1.07–1.54)

1.29(1.08–1.55)

 No. of MetS components

0

12,979

164,307.06

43

Ref

Ref

1

25,627

318,630.72

105

0.98(0.69–1.40)

0.99(0.69–1.41)

2

28,010

345,333.67

139

1.07(0.76–1.50)

1.08(0.77–1.53)

3

19,938

243,003.49

122

1.28(0.90–1.81)

1.30(0.92–1.84)

4–5

11,421

137,903.70

76

1.38(0.95–2.00)

1.39(0.96–2.03)

p_trend

0.008

0.007

Kidney cancer

 MetS status

Non-MetS

66,616

829,139.77

88

Ref

Ref

MetS

31,359

381,403.48

77

1.74(1.28–2.36)

1.74(1.28–2.37)

 No. of MetS components

0

12,979

164,421.30

12

Ref

Ref

1

25,627

318,972.08

30

1.15(0.59–2.24)

1.16(0.59–2.27)

2

28,010

345,746.39

46

1.53(0.81–2.90)

1.56(0.82–2.95)

3

19,938

243,335.17

42

1.93(1.01–3.69)

1.96(1.03–3.75)

4–5

11,421

138,068.32

35

2.79(1.44–5.41)

2.82(1.46–5.47)

p_trend

 < 0.001

 < 0.001

Prostate cancer

 MetS status

Non-MetS

66,616

829,318.96

75

Ref

Ref

MetS

31,359

381,647.01

59

1.47(1.04–2.06)

1.47(1.04–2.07)

 No. of MetS components

0

12,979

164,450.99

11

Ref

Ref

1

25,627

319,007.40

28

0.92(0.46–1.86)

0.92(0.46–1.84)

2

28,010

345,860.57

36

0.96(0.49–1.89)

0.95(0.48–1.86)

3

19,938

243,468.49

39

1.44(0.74–2.82)

1.43(0.73–2.80)

4–5

11,421

138,178.52

20

1.31(0.63–2.73)

1.30(0.62–2.71)

p_trend

0.085

0.088

Bladder cancer

 MetS status

Non-MetS

66,616

829,035.72

105

Ref

Ref

MetS

31,359

381,627.63

53

0.93(0.67–1.29)

0.93(0.67–1.30)

 No. of MetS components

0

12,979

164,396.49

17

Ref

Ref

1

25,627

318,911.15

39

0.87(0.49–1.55)

0.89(0.50–1.57)

2

28,010

345,728.08

49

0.89(0.51–1.55)

0.91(0.52–1.58)

3

19,938

243,447.21

37

0.92(0.51–1.63)

0.94(0.53–1.67)

4–5

11,421

138,180.42

16

0.69(0.35–1.37)

0.70(0.35–1.39)

p_trend

0.444

0.479